GlassScriptPhysician profile
Ernesto Lajara
NPI 1083183859
$4,945.23
in general payments reported to CMS, 2019-2025
22 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $2,441 · 2023: $635 · 2024: $171 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $645.76 | 2021-2024 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $632.33 | 2021-2023 | Spravato |
| Abbvie INC. | $507.09 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $484.55 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $456.82 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $348.61 | 2021-2024 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $302.26 | 2021-2025 | Ingrezza |
| Luye Pharma (USA) LTD. | $251.87 | 2025 | Erzofri Extended-Release |
| Indivior INC. | $236.90 | 2021-2023 | Perseris |
| Pear Therapeutics (US), INC. | $208.32 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.52 | 2021-2023 | |
| Lundbeck LLC | $158.95 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $143.12 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $126.60 | 2022-2025 | Auvelity |
| Corium, LLC | $60.17 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $53.73 | 2022-2023 | Jornay Pm |
| Almatica Pharma LLC | $37.46 | 2022 | |
| Sunovion Pharmaceuticals INC. | $36.32 | 2021 | |
| Bausch Health US, LLC | $21.03 | 2023 | Aplenzin |
| Vanda Pharmaceuticals INC. | $20.88 | 2021 | |
| Adlon Therapeutics L.P. | $19.75 | 2021 | |
| Merck Sharp & Dohme LLC | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Lajara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.